BioVie Inc (NASDAQ:BIVI) told investors it will host a virtual KOL event at 2:30pm ET today, September 7, 2023, titled NE3107―Putting Data in Context, ahead of the upcoming Phase 3 results in Alzheimer’s Disease.
The event will focus on BioVie’s lead product candidate, NE3107, currently in a potentially pivotal Phase 3 study in patients with mild to moderate Alzheimer’s disease with expected topline data readout in the fourth quarter of 2023.
BioVie said its leadership team and Key Opinion Leader (KOL) Dr Steven Arnold will discuss the totality of NE3107 data generated to date.